Primary Responsibilities: Informing development strategies from HEOR / market access perspective Represent the HEOR and market access perspective in internal clinical development and regulatory forums Provide critical input into clinical development plans, including protocol design, endpoint selection, and other aspects of clinical trial evidence generation, to ensure alignment with future payer and HTA expectations Communication of value to payers and HTA bodies Lead development of AMCP dossiers for US payers Lead development of cost-effectiveness models for NICE and other HTA bodies requiring formal cost-effectiveness analyses Serve as a core team member for HTA submissions outside the US, with responsibility for shaping and stress-testing value narratives included in pricing and reimbursement dossiers and interpreting and recommending evidence to support such narratives, in a way that optimizes both credibility and relevance for payer decision-making Make substantial contributions to other payer communication materials (e.g., Medical Value Liaison slide decks) and launch readiness activities as needed Leading real-world evidence strategy and execution of real-world analyses Lead planning of real-world evidence generation activities to address evidence gaps as needed for informing decision-making by payers, HTA bodies, and clinicians Oversee execution of real-world data analyses, ensuring analytical rigor and fitness for purpose Interpret and translate results from real-world analyses into peer-reviewed publications and other external communications intended to meaningfully inform clinical practice and payer/HTA decision-making. Accordingly, the Director, Global HEOR, helps shape development plans, evidence strategies, and value narratives so that they align with how payers and health technology assessment (HTA) bodies make decisions, balancing analytical rigor with a clear focus on what is relevant for decision-making.